AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
Phase 2
Completed
- Conditions
- Squamous Cell CancerCancer of Head and Neck
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT00255476
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia
Phase 4
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: conventional treatment for schizophrenia
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 85
- Registration Number
- NCT00255515
- Locations
- 🇸🇪
Research Site, Vasteras, Sweden
Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2007-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 144
- Registration Number
- NCT00255528
- Locations
- 🇩🇴
Research Site, Santo Domingo, Dominican Republic
Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 185
- Registration Number
- NCT00255463
- Locations
- 🇬🇧
Research Site, Poole, United Kingdom
GALLANT 4 Tesaglitazar vs. Glibenclamide
Phase 3
Terminated
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 580
- Registration Number
- NCT00255541
- Locations
- 🇹🇭
Research Site, Bangkok, Thailand
G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)
Terminated
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4500
- Registration Number
- NCT00255645
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-11-18
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00255255
- Locations
- 🇯🇵
Research Site, Kochi, Japan
Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation
Phase 2
Completed
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2005-11-18
- Last Posted Date
- 2007-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 160
- Registration Number
- NCT00255281
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
CMAB vs IMAB in Metastatic Prostate Cancer
Phase 4
Withdrawn
- Conditions
- Metastatic Prostate Cancer
- First Posted Date
- 2005-11-18
- Last Posted Date
- 2007-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT00255268
- Locations
- 🇲🇽
Research Site, Mexico City, Mexico
Quetiapine Augmentation in Severe Obsessive Compulsive Disorder
Phase 3
Completed
- Conditions
- Obsessive Compulsive Disorder
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT00254735
- Locations
- 🇩🇪
Research Site, Lübeck, Germany
© Copyright 2025. All Rights Reserved by MedPath